Rachel Koransky-Matson
Nurse Practitioner · Bangor, MENPI 1407307861
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Lilly USA, LLC at 49.2% of the total. 2025 is the largest year on record at $9,157, 3.8 times the $2,404 reported in 2022. Among nurse practitioner clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 162 payments — averaging $98.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$8K
- Medtronic$4K
- Dexcom, Inc.$749
- Abbott$686
- Tandem Diabetes Care, Inc.$600
- AstraZeneca$563
- plus $1K from 13 others
What the payments were for
- Speaking & faculty fees$7,20045%
- Travel & lodging$3,80924%
- Food & beverage$4,66629%
- Education$1221%
- Other$1601%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 18 | $7,850 |
| Medtronic | 67 | $4,462 |
| Dexcom, Inc. | 12 | $749 |
| Abbott | 9 | $686 |
| Tandem Diabetes Care, Inc. | 17 | $600 |
| AstraZeneca | 13 | $563 |
| Novo Nordisk | 8 | $211 |
| BETA Bionics, Inc. | 4 | $152 |
| Sequel Med Tech, LLC | 1 | $124 |
| Supernus Pharmaceuticals, Inc. | 1 | $121 |
| Sanofi-aventis U.S. LLC | 1 | $104 |
| Ipsen Biopharmaceuticals, Inc | 1 | $90 |
| Boehringer Ingelheim | 2 | $53 |
| Amgen | 2 | $50 |
| Averitas Pharma Inc. | 1 | $40 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Exact Sciences | 1 | $26 |
| Corcept Therapeutics | 1 | $25 |
| Insulet Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$7,200
- MINIMED 780G$1,373
- MINIMED 770G$1,317
- FREESTYLE LIBRE 3$396
- DEXCOM G6 TRANSMITTER$270
- DEXCOM G7 GSS (161)$158
- DEXCOM STELO GLUCOSE BIOSENSOR$158
- AIRSUPRA$125
- TWIIST$124
- QELBREE$121
- LOKELMA$115
- INTELLIS ADAPTIVESTIM$112
- FREESTYLE COPILOT$110
- TZIELD$104
How this compares
$15,957 in reported general payments places this provider in the 95th percentile of 740 nurse practitioner providers in Maine.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 271 | $371,930 |
| OzempicSemaglutide | 252 | $300,347 |
| JardianceEmpagliflozin | 104 | $158,248 |
| Tresiba Flextouch U-200Insulin Degludec | 91 | $131,065 |
| MounjaroTirzepatide | 87 | $114,548 |
| FarxigaDapagliflozin Propanediol | 106 | $111,048 |
| RybelsusSemaglutide | 33 | $55,562 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 39 | $32,144 |
| Tresiba Flextouch U-100Insulin Degludec | 49 | $32,012 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $30,160 |
| JanuviaSitagliptin Phosphate | 27 | $25,987 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 12 | $16,820 |
| HumalogInsulin Lispro | 39 | $15,792 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 78 | $11,850 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 30 | $11,467 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $7,850 | $502,271397 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $211 | $360,265299 claims |
| Boehringer IngelheimJardiance | $53 | $158,248104 claims |
| AstraZenecaFarxiga | $563 | $111,048106 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 740 nurse practitioner providers in Maine.
Other nurse practitioner in Bangor
- Lyudmila GazderBangor$822
- Chloe MartinBangor$790
- Amy LangleyBangor$737
- Frank BreznyakBangor$447
- Amanda MagnoliWestbrook$113K
- Gisele CastonguayLewiston$26K
- Denise ViekmanPortland$15K
- Kerri NeelYork$5K
- Mallory EvansYork$5K
- Karrie SweetPortland$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.